T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)
Nov 2024
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Development
Guideline Objective
To provide recommendations and identify considerations around cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving T-cell engaging antibody treatment.
Patient Population
Adults receiving treatment with a T-cell engaging antibody.
Intended Guideline Users
Clinicians treating patients receiving a T-cell engaging antibody and/or managing possible toxicities, including CRS and/or ICANS.
Research Questions
- What prophylactic measures are needed to help prevent CRS and ICANS?
- Is there a role for prophylactic tocilizumab?
- Can the premedications be standardized across T-cell engaging antibodies?
- Are there specific patient groups who are at a higher risk of experiencing CRS and ICANS?
- What is the appropriate management of CRS based on grade?
- What is the appropriate management of ICANS based on grade?
- What factors should be taken into consideration for the outpatient administration of ramp-up doses?
The clinical guidance report is under development for release.
If you are a patient, please contact your oncology care team if you have concerns or issues in the interim.